Emergent closes on buying smallpox drug Tembexa from Chimerix with a $238M payment
It was only last year that the oral treatment Tembexa was approved by the FDA to treat smallpox, but the drug has already changed hands.
Emergent BioSolutions, one of the primary drug manufacturers for the US government, has grabbed the global rights for Tembexa from the North Carolina-based biotech Chimerix. And that’s not the only thing that Emergent is picking up.
The manufacturer will also get Chimerix’s 10-year BARDA contract to produce 1.7 million doses of the drug. The value of the contract sits at $680 million as well as a “product procurement” valued at $115 million. Additional options are valued at $551 million, which can be committed at BARDA’s discretion.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.